ストックスクリーナーアプリを入手
700.33
0.62%
4.31
アフターアワーズ：
700.33
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
2025-02-21 | Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders | NDAQ:REGN | Press Release - Stockhouse Publishing
Braun Stacey Associates Inc. Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire
BMY: 3 Precision Medicine Stocks That Could Transform Healthcare - StockNews.com
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman - GlobeNewswire
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) - GlobeNewswire
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Price Over Earnings Overview: Regeneron Pharmaceuticals - Benzinga
2025-02-21 | Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN) | NDAQ:REGN | Press Release - Stockhouse Publishing
Korean court rules in favor of Samsung Bioepis over Regeneron’s Eylea - Korea Economic Daily
Handelsbanken Fonder AB Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Principal Securities Inc. Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Allworth Financial LP Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Everhart Financial Group Inc. Sells 508 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Hussman Strategic Advisors Inc. Purchases Shares of 2,100 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2025-02-20 | Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN) | NDAQ:REGN | Press Release - Stockhouse Publishing
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure ... - The Bakersfield Californian
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman - TradingView
Shareholders that lost money on Regeneron Pharmaceuticals, - GlobeNewswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - PR Newswire
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Fagan Associates Inc. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before March 10, 2025 to Discuss Your RightsREGN - PR Newswire
Alberta Investment Management Corp Invests $5.06 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Rhumbline Advisers Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
842 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Kornitzer Capital Management Inc. KS - MarketBeat
ABC Arbitrage SA Buys New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2025-02-19 | Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsREGN | NDAQ:REGN | Press Release - Stockhouse Publishing
US must meet tougher standard in Regeneron kickback lawsuit - Reuters
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
2025-02-19 | Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky | NDAQ:REGN | Press Release - Stockhouse Publishing
Regeneron Class Action: Join by March 10, 2025 – Contact Levi & Korsinsky - The Octant
Callahan Advisors LLC Acquires Shares of 866 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Kestra Investment Management LLC Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Truist Financial Corp Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Principal Financial Group Inc. - MarketBeat
REGN STOCK NEWS: Robbins LLP Reminds Regeneron - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - TradingView
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron Gets Appeals Court to Impose Tougher Kickback Standard - Bloomberg Law
Regeneron Pharmaceuticals, Inc. Securities Fraud Class - GlobeNewswire
Acute Gout Flare Market to Reach New Heights in Growth by 2034, - openPR
Regeneron, Sanofi win FDA review for Dupixent update (REGN) (REGN:NASDAQ) - Seeking Alpha
This Company Just Initiated a Quarterly Dividend: Time to Buy? - MSN
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid - Pharmaceutical Technology
CIBC Asset Management Inc Has $24.49 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Montag A & Associates Inc. Sells 644 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Asset Management One Co. Ltd. Purchases 3,504 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP) - The Manila Times
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid - GlobeNewswire
Allspring Global Investments Holdings LLC Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Banque Pictet & Cie SA Buys Shares of 6,312 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Acquired Rep. Julie Johnson - MarketBeat
ROSEN, A GLOBALLY RESPECTED LAW FIRM , Encourages Regeneron Pharmaceuticals, Inc. Investors to ... - The Bakersfield Californian
ROSEN, A GLOBALLY RESPECTED LAW FIRM , Encourages Regeneron - GlobeNewswire
2025-02-17 | Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineREGN | NDAQ:REGN | Press Release - Stockhouse Publishing
Regeneron Pharmaceuticals (REGN) Faces Securities Class - GlobeNewswire
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Regeneron Pharmaceuticals, Inc. to Contact the Firm Today! - Markets Insider
0.46%
0.81%
大文字化:
|
ボリューム (24 時間):